Processing

Please wait...

Settings

Settings

1. WO2016193241 - COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Publication Number WO/2016/193241
Publication Date 08.12.2016
International Application No. PCT/EP2016/062226
International Filing Date 31.05.2016
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
453
Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
02
containing not further condensed quinuclidine ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4709
Non-condensed quinolines containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
C07D 453/02 (2006.01)
A61K 31/4709 (2006.01)
A61P 11/00 (2006.01)
CPC
A61K 31/4709
A61K 9/0073
A61M 15/009
A61M 16/14
A61M 2202/064
A61P 11/00
Applicants
  • CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A 43100 Parma, IT
Inventors
  • CARZANIGA, Laura; IT
  • RANCATI, Fabio; IT
  • RIZZI, Andrea; IT
  • LINNEY, Ian; IT
  • SCHMIDT, Wolfgang; IT
  • BARNES, Michael; IT
  • KNIGHT, Chris; IT
Agents
  • MINOJA, Fabrizio; IT
Priority Data
15170033.301.06.2015EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
(FR) COMPOSÉS AYANT UNE ACTIVITÉ D'ANTAGONISTE DES RÉCEPTEURS MUSCARINIQUES ET D'AGONISTE DES RÉCEPTEUR ADRÉNERGIQUES BÊTA 2
Abstract
(EN)
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.
(FR)
La présente invention concerne des composés agissant à la fois comme antagonistes des récepteurs muscariniques et comme agonistes des récepteurs adrénergiques bêta2, ainsi que des procédés de préparation de ceux-ci, des compositions les comprenant, des utilisations thérapeutiques et des combinaisons avec d'autres principes actifs pharmaceutiques.
Latest bibliographic data on file with the International Bureau